Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

2.310 -0.130 (-5.33%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,151,441
Open	2.440
Bid (Size)	2.320 (9,000)
Ask (Size)	2.350 (700)
Prev. Close	2.440
Today's Range	2.260 - 2.510
52wk Range	1.410 - 4.340
Shares Outstanding	27,132,588
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

January 07, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

January 06, 2026

Results to be discussed in KOL event today at 10 a.m. ET

From Gain Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-27.4%	-27.4%
1 Month	-43.8%	-43.8%
3 Month	+21.6%	+21.6%
6 Month	+24.2%	+24.2%
1 Year	+0.4%	+0.4%

More News

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

December 18, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Keep an eye on the top gainers and losers in Thursday's session. ↗

December 18, 2025

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

December 18, 2025

Via Chartmill

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease

December 18, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

November 20, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

November 12, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics to Present at Neuroscience 2025

October 30, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

October 16, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

October 09, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®

October 06, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

September 23, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease

September 18, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

September 04, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

August 12, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 08, 2025

Via Benzinga

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

July 24, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

July 16, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 16, 2025

Via Benzinga

US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus ↗

July 16, 2025

Via Benzinga

Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket ↗

July 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 15, 2025

Via Benzinga

Tuesday's after hours session: top gainers and losers ↗

July 15, 2025

Via Chartmill

Gain Therapeutics Announces Proposed Public Offering

July 15, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Gain Therapeutics, Inc. - Common Stock publicly traded?

Yes, Gain Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Gain Therapeutics, Inc. - Common Stock trade on?

Gain Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Gain Therapeutics, Inc. - Common Stock?

The ticker symbol for Gain Therapeutics, Inc. - Common Stock is GANX on the Nasdaq Stock Market

What is the current price of Gain Therapeutics, Inc. - Common Stock?

The current price of Gain Therapeutics, Inc. - Common Stock is 2.310

When was Gain Therapeutics, Inc. - Common Stock last traded?

The last trade of Gain Therapeutics, Inc. - Common Stock was at 01/09/26 04:00 PM ET

What is the market capitalization of Gain Therapeutics, Inc. - Common Stock?

The market capitalization of Gain Therapeutics, Inc. - Common Stock is 62.68M

How many shares of Gain Therapeutics, Inc. - Common Stock are outstanding?

Gain Therapeutics, Inc. - Common Stock has 63M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.